This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Robert J. Holt, PharmD
GD Searle & Co Skokie, Ill

JAMA. 1997;277(18):1434.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The findings of Soumerai et al¹ lump all calcium channel blockers into one group. While no calcium channel blocker is currently approved by the Food and Drug Administration for prevention of morbidity and mortality post-MI, data from several studies have shown that verapamil can reduce morbidity and mortality in some post-MI patients.

The Second Danish Verapamil Infarction Trial (DAVIT II)^2,3 randomized patients (<76 years of age) 7 to 15 days after hospital admission for AMI to receive either 120 mg of immediate-release verapamil 3 times per day (n=878) or placebo 3 times per day (n=897) for 12 to 18 months. Among the verapamil-treated patients, 289 were 65 years of age or older. In the intent-to-treat analyses for the total study population, verapamil was associated with a nonsignificant reduction in the 18-month mortality rate (20%) and a significant reduction in the major event (20%) rate vs placebo. Subgroup analysis . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?